The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones
Abstract
The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and topoisomerase IV, both of which are involved in DNA replication. Quinolones form complexes of these enzymes with DNA, complexes that block movement of the DNA-replication fork and thereby inhibit DNA replication. Many older quinolones differ in their relative activities against gyrase and topoisomerase IV in a bacterial cell, having greater potency against gyrase than against topoisomerase IV in many gram-negative bacteria and greater potency against topoisomerase IV than against gyrase in many gram-positive bacteria. Several newer quinolones appear to have more closely balanced activity against these enzymes. Resistance to fluoroquinolones occurs as a result of mutational amino acid substitutions in the subunits of the more sensitive (or primary-target) enzyme within the cell. If, however, both enzymes are similarly susceptible to a fluoroquinolone, then the level of resistance caused by a primary-target mutation may be low and may be limited by the sensitivity of the secondary target. Fluoroquinolones also differ in the extent to which common bacterial multidrug efflux pumps affect their activity, with some compounds being unaffected by resistance mechanisms because of overexpression of such pumps. Newer fluoroquinolone interaction with dual targets and avoidance of efflux-resistance mechanisms may each contribute to the lower frequencies of selection of resistant mutants in the laboratory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, J. C. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.003223 · Cited by 1,832
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Mechanisms of fluoroquinolone resistance
Hooper, D. C. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0068 · Cited by 488
Self-citationYoshida, H., Bogaki, M., Nakamura, S., Ubukata, K., & Konno, M. (1990) · Journal of Bacteriology · doi:10.1128/jb.172.12.6942-6949.1990 · Cited by 479
Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus
Kaatz, G. W., Seo, S. M., & Ruble, C. A. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1086 · Cited by 413
Topoisomerase IV is a target of quinolones in Escherichia coli.
Khodursky, A. B., Zechiedrich, E. L., & Cozzarelli, N. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11801 · Cited by 378
Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A., & Blanche, F. (1994) · Molecular Microbiology · doi:10.1111/j.1365-2958.1994.tb00458.x · Cited by 378
Gill, M. J., Brenwald, N. P., & Wise, R. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.187 · Cited by 259
Ng, E. Y., Trucksis, M., & Hooper, D. C. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1881 · Cited by 232
Self-citationNg, E. Y., Trucksis, M., & Hooper, D. C. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1345 · Cited by 226
Self-citation
Cited by
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Multidrug Resistance in Bacteria
Nikaido, H. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082907.145923 · Cited by 1,682
Rai, M. K., Deshmukh, S. D., Ingle, A. P., & Gade, A. K. (2012) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2012.05253.x · Cited by 1,524
Acquired Antibiotic Resistance Genes: An Overview
van Hoek, A. H. A. M., Mevius, D., Guerra, B., Mullany, P., Roberts, A. P., & Aarts, H. J. M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00203 · Cited by 1,136
Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
Redgrave, L. S., Sutton, S. B., Webber, M. A., & Piddock, L. J. V. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.007 · Cited by 1,008
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2004) · Drugs · doi:10.2165/00003495-200464020-00004 · Cited by 798
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
Mitscher, L. A. (2005) · Chemical Reviews · doi:10.1021/cr030101q · Cited by 781
Mechanisms of antibiotic resistance in enterococci
Miller, W. R., Munita, J. M., & Arias, C. A. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956092 · Cited by 772
Prevalence in the United States of aac(6 ′ ) - Ib - cr Encoding a Ciprofloxacin-Modifying Enzyme
Park, C. H., Robicsek, A., Jacoby, G. A., Sahm, D., & Hooper, D. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00915-06 · Cited by 757
Self-citationHow to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
Neuhauser, M. M., Weinstein, R. A., Rydman, R., Danziger, L. H., Karam, G., & Quinn, J. P. (2003) · JAMA · doi:10.1001/jama.289.7.885 · Cited by 678
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Bacterial efflux pump inhibitors from natural sources
Stavri, M., Piddock, L. J. V., & Gibbons, S. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl460 · Cited by 547
Mechanisms of bacterial biocide and antibiotic resistance: ANTIBIOTIC AND BIOCIDE RESISTANCE
Poole, K. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.8.x · Cited by 513
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Plasmid-Mediated Quinolone Resistance in Clinical Isolates of Escherichia coli from Shanghai, China
Wang, M., Tran, J. H., Jacoby, G. A., Zhang, Y., Wang, F., & Hooper, D. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2242-2248.2003 · Cited by 467
Self-citationLomovskaya, O., & Bostian, K. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.008 · Cited by 460
Klebsiella pneumoniae AcrAB Efflux Pump Contributes to Antimicrobial Resistance and Virulence
Padilla, E., Llobet, E., Doménech-Sánchez, A., Martínez-Martínez, L., Bengoechea, J. A., & Albertí, S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00715-09 · Cited by 431
Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae
Nordmann, P., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki245 · Cited by 425
Fluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
Antibiotic Resistances of Starter and Probiotic Strains of Lactic Acid Bacteria
Hummel, A. S., Hertel, C., Holzapfel, W. H., & Franz, C. M. A. P. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.02105-06 · Cited by 390
Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
Dalhoff, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/976273 · Cited by 354
Johnson, J. R., Murray, A. C., Gajewski, A., Sullivan, M., Snippes, P., Kuskowski, M. A., & Smith, K. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2161-2168.2003 · Cited by 346
Prevalence of Plasmid-Mediated Quinolone Resistance Determinants over a 9-Year Period
Kim, H. B., Park, C. H., Kim, C. J., Kim, E.-C., Jacoby, G. A., & Hooper, D. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01051-08 · Cited by 339
Self-citationAntibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective
Sultan, I., Rahman, S., Jan, A. T., Siddiqui, M. T., Mondal, A. H., & Haq, Q. M. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02066 · Cited by 320
Multi-targeting by monotherapeutic antibacterials
Silver, L. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Repair of and checkpoint response to topoisomerase I-mediated DNA damage
Pommier, Y., Redon, C., Rao, V. A., Seiler, J. A., Sordet, O., Takemura, H., Antony, S., Meng, L., Liao, Z., Kohlhagen, G., et al. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.08.016 · Cited by 302
Poirel, L., Cattoir, V., & Nordmann, P. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00024 · Cited by 276
Abrupt Emergence of a Single Dominant Multidrug-Resistant Strain of Escherichia coli
Johnson, J. R., Tchesnokova, V., Johnston, B., Clabots, C., Roberts, P. L., Billig, M., Riddell, K., Rogers, P., Qin, X., Butler-Wu, S., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis933 · Cited by 269
Self-citationGrillon, A., Schramm, F., Kleinberg, M., & Jehl, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156690 · Cited by 124
Discovery of disease-adapted bacterial lineages in inflammatory bowel diseases
Kumbhari, A., Cheng, T. N. H., Ananthakrishnan, A. N., Kochar, B., Burke, K. E., Shannon, K., Lau, H., Xavier, R. J., & Smillie, C. S. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.05.022 · Cited by 54
Abdelkader, M. M., Aboshanab, K. M., El-Ashry, M. A., & Aboulwafa, M. M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171349 · Cited by 44
Metadata
- Authors
- Hooper, D. C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-08-01
- Volume
- 31
- Issue
- Supplement_2
- Pages
- S24-S28
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2149410208
- Cited by
- 409
- References
- 22
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.